This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -39.13% and 0.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
UTHR vs. CORT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
UTHR vs. CORT: Which Stock Is the Better Value Option?
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022. Shares down in after-hours trading.
Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 30.43% and 5.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS
by Zacks Equity Research
Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.
Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Corcept (CORT) Down 8.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ASRT or CORT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. CORT: Which Stock Is the Better Value Option?
JAZZ or CORT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. CORT: Which Stock Is the Better Value Option?
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.
Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -4% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Corcept Therapeutics (CORT) and Alkermes (ALKS) have performed compared to their sector so far this year.
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
ProPhase Labs, Inc. (PRPH) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.